Farydak® (panobinostat) – Voluntary withdrawal
November 30, 2021 - Secura Bio announced, based on discussions with the FDA, that they have submitted for the withdrawal of the approval of Farydak (panobinostat), for use in combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent.
Top